http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012085249-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7d799b9644c8c8178a28bd44023d3f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_207c148d0cfc11d05383db5abcce58d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9e2f727a1cc696be58053bcc6c82ebf1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f4c61c663e0dae806db45a169df672f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8fc5210ad36dce22387934b7a2fb8d42
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-401
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
filingDate 2011-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5f1734950a20c247f3b123de6003ebb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_074681d39d1e68e45a4e1a48b6cabb82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c320096af403374f81ab02eaa33a785
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4621cba0dca23484b6c59d7022601774
publicationDate 2012-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2012085249-A3
titleOfInvention Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
abstract The invention relates to pharmaceutical oral dosage forms of the active substances lercanidipine and enalapril, as well the pharmacologically acceptable salts thereof, characterized in that the pharmaceutical oral dosage forms comprise an organic acid to stabilize both enalapril and lercanidipine, and their pharmaceutically acceptable salts.
priorityDate 2010-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005053689-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4830853-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0066116-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0119348-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65866
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5388962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393239
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413385
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413386
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9809926

Total number of triples: 34.